Poster presentation describing the significant results of crofelemer for cancer therapy-related diarrhea (ctd) in breast cancer patients to take place december 11, 2024 at san antonio breast cancer symposium (sabcs)

Adult patients with breast cancer are a prespecified subgroup of the recently conducted ontarget trial evaluating crofelemer for prophylaxis of ctd san francisco, ca / accesswire / december 9, 2024 / jaguar health, inc. (nasdaq:jagx) (jaguar) family company napo pharmaceuticals (napo) today announced that the data from the recently conducted analysis of the prespecified subgroup of adult patients with breast cancer from the phase 3 ontarget trial, which indicate that crofelemer achieved significant results in this subgroup, will be the subject of a poster presentation on december 11, 2024 during the 12:30 - 2:00 p.m. cst poster session 1 at the san antonio breast cancer symposium (sabcs), which takes place december 10-13, 2024 in san antonio, texas.
JAGX Ratings Summary
JAGX Quant Ranking